Vise Technologies’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$221K Buy
2,825
+225
+9% +$18.1K 0.02% 728
2024
Q3
$209K Sell
2,600
-973
-27% -$78.6K 0.03% 556
2024
Q2
$296K Buy
+3,573
New +$314K 0.05% 315
2023
Q4
Sell
-5,367
Closed -$481K 359
2023
Q3
$481K Sell
5,367
-2,871
-35% -$256K 0.12% 175
2023
Q2
$701K Buy
8,238
+3,020
+58% +$255K 0.17% 129
2023
Q1
$432K Buy
5,218
+960
+23% +$77.7K 0.11% 184
2022
Q4
$335K Buy
4,258
+946
+29% +$76K 0.1% 212
2022
Q3
$245K Buy
+3,312
New +$238K 0.09% 246

Other funds holding HAE

Vise Technologies's HAE Position: Q4 2024 in Review

Vise Technologies increased its Haemonetics (HAE) stake by 8.7% in Q4 2024, buying an estimated $18.1K and bringing the position to 2,825 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #728.

Vise Technologies first reported a position in HAE in Q3 2022 and has held it in 8 quarters since. The position peaked at $701K in Q2 2023. 309 funds tracked by Wall St. Rank hold HAE as of Q4 2024.

  • Vise Technologies held 2,825 shares of Haemonetics worth $221K as of Q4 2024.
  • Vise Technologies bought 225 Haemonetics shares in Q4 2024, an estimated $18.1K.
  • Haemonetics made up 0.02% of Vise Technologies's portfolio in Q4 2024, its #728 holding.
  • Vise Technologies first reported a position in Haemonetics in Q3 2022 and has held it in 8 quarters since.
  • Vise Technologies's Haemonetics position peaked at $701K in Q2 2023.
  • 309 funds tracked by Wall St. Rank held Haemonetics as of Q4 2024.

Based on Vise Technologies's 13F filing for Q4 2024, filed 18 Feb 2025.